Denmark· DK-28104424608
Montelukast "Sandoz"
A montelukast product containing montelukastnatrium, registered in Denmark by Sandoz A/S. The same ATC class is registered in 19 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Montelukast is registered in 19 of 19 countries.
Countries holding a registration under ATC R03DC03 (montelukast), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 11 of them publish a price we can compare per daily dose
Montelukast · ATC R03DC03
19 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of montelukast costs, country by country.
Normalised to the WHO defined daily dose (10 mg), the median price runs from $0.59 in Italy to $1.71 in Spain — a ×2.9 gap.
- 4 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Montelukast · price per daily dose (10 mg)
USD · FX 28 Sept 2026
- ES Spain$1.71
- CH Switzerland$1.41
- FR France$0.71
- IT Italy$0.59
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- MONTELUKASTNATRIUM
- Manufacturer
- Sandoz A/S
- Country
- Denmark (DK)
- ATC code
- R03DC03
- ATC class
- Montelukast
- Defined daily dose
- 10 mg, O
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28104424608
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
565 interactions on record for montelukast.
Graded by severity as the source publishes them — 101 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Montelukast · interactions on record
565 records
- 101 moderate
- 464 info
Most severe, free to view
- MiconazoleA07AC01moderate
- TroglitazoneA10BG01moderate
- NateglinideA10BX03moderate
- NitisinoneA16AX04moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under R03DC03
Montelukast, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ed7932f7-00e9-4e57-960c-4e94fed70c32 GET /v1/drugs/ed7932f7-00e9-4e57-960c-4e94fed70c32?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "tyggetabletter",
"source": "dkma",
"strength": "5 mg",
"auth_role": "CMS",
"dk_drugid": "28104424608",
"substance": "MONTELUKASTNATRIUM",
"auth_procedure": "Decentral procedure",
"in_medicinpriser": true,
"registration_date_serial": "40350"
}See everything about montelukast.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.